|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE JOHNSON & JOHNSON PLAZA |
Address2 |
|
City | NEW BRUNSWICK |
State | NJ |
Zip Code | 08933 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 20686-12
|
||||||||
|
6. House ID# 303480000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Donald W. Bohn |
Date | 1/23/2017 6:08:26 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
- HR 1270/S 709, "Restoring Access to Medication Act of 2015", regarding all provisions.
- Issues related to tax reform.
- Issues related to CFC Look through permanency.
- Issues related to R&D credit.
- Issues related to Mobile Workforce legislation.
- Issues related to Cadillac Tax.
- Issues related to OECD tax reporting.
- Issues related to Repatriation holiday.
- Issues related to Puerto Rico tax treatment.
- Issues related to flexible spending accounts tax treatment.
- HR 4900/ HR 5278/ S 2328, "PROMESA", regarding provisions related to Puerto Rico debt restructuring.
- H.Res 770, "Providing for consideration of the bill (H.R. 5278) to establish an Oversight Board to assist the Government of Puerto Rico, including instrumentalities, in managing its public finances, and for other purposes.", regarding all provisions.
- Issues related to treasury debt/equity rules.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
|
Darrel |
Jodrey |
|
|
|
Pedro |
Costa |
|
|
|
Anne |
Oswalt |
|
|
|
Brian |
Burns |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
- H 2, "Medicare Access and CHIP Reauthorization Act of 2015", regarding all provisions.
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions.
- S 1622, "FDA Device Accountability Act of 2015", regarding all provisions.
- HR 6, "21st Century Cures Act", regarding all provisions.
- S 993, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
- Issues related to physician-owned companies that manufacture or distribute medical devices.
- Issues relating to cosmetic regulatory reform.
- Issues related to 340B payments to hospitals.
- Issues related to pseudoephedrine.
- Issues related to dextromethorphan.
- Issues related to legislation that would modify the Medicare Part B drug reimbursement program.
- Issues related to legislation that would establish a rebate in the Medicare Part D program.
- Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule.
- S.2977, "The Medical Electronic Data Technology Enhancement for Consumers' Health" (MEDTECH Act), regarding all provisions.
- H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions.
- S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions.
- S. 1767, "The Combination Products Regulatory Fairness Act of 2015", regarding all provisions.
- HR 2646, "Helping Families in Mental Health Crisis Act of 2015", regarding all provisions.
- HR 1854, "Comprehensive Justice and Mental Health Act of 2015", regarding all provisions.
- S. 1014, "Personal Care Products Safety Act", regarding all provisions.
- S. 2777, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions.
- Issues related to Medicare Part B Demo
- Issues related to Expanded Access in Senate Innovation Package
- Issues related to Self monitoring of blood glucose meters.
- HR 4075, "Cosmetic Modernization Amendments of 2015", regarding all provisions.
- HR 1192, "National Clinical Care Commission Act", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Lauryl |
Jackson |
|
|
|
Darrel |
Jodrey |
|
|
|
Mark |
Reese |
|
|
|
Anne |
Oswalt |
|
|
|
Charles |
Nau |
|
|
|
Brian |
Burns |
|
|
|
Brian |
Kelly |
|
|
|
David |
Kavanaugh |
|
|
|
Carla |
Cartwright |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
- S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
- Issues relating to animal testing.
- HR 2858, "Humane Cosmetics Act", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
- HR 83, "Consolidate and Further Continuing Appropriations Act, 2015", provisions related to emergency supplemental funding to address the Ebola epidemic domestically and internationally.
- Issues related to the funding of the Biomedical Advanced Research and Development Authority.
- Issues related to FDA Funding.
- Issues related to VA procurement.
- S. 3067/ HR 5485 - Financial Services and General Appropriations Act of 2017
- Issues related to FTC funding.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Brian |
Burns |
|
|
|
Charles |
Nau |
|
|
|
Jane |
Adams |
|
|
|
Anne |
Oswalt |
|
|
|
Brian |
Kelly |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
- Issues related to Trans-Pacific Partnership agreement.
- Issues related to Transatlantic Trade and Investment Partnership.
- Issues related to the appointment of a dedicated healthcare trade official
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
- HR 1427/S 804, "Medicare CGM Access Act of 2015", regarding all provisions.
- HR 284, "Medicare DMEPOS Competitive Bidding Improvement Act of 2015", regarding all provisions.
- Issues regarding combination products.
- Issues regarding Transferable Regulatory Exclusivity Incentive.
- Issues related to Expanded Access.
- S. 2736/ HR 5210, "Patient Access to Durable Medical Equipment Act of 2016", regarding all provisions.
- Issues related to competitive bidding for DME products.
- S. 2484, "Connect for Health Act", Provisions related to expanded use of RPM for certain patients with chronic conditions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Mark |
Reese |
|
|
|
Brian |
Kelly |
|
|
|
Anne |
Oswalt |
|
|
|
Lauryl |
Jackson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
- HR 9, "Goodlatte Innovation Act", regarding all provisions
- S 632, "STRONG Patents Act of 2015", regarding all provisions
- Issues related to the re-introduction of the Patent Abuse Act
- Issues related to BARDA and other Ebola related matters.
- Issues related to biosimilar reform.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Nau |
|
|
|
Jane |
Adams |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |